Advantages and limitations of next-generation sequencing technologies: A comparison of electrophoresis and non-electrophoresis methods

Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Electrophoresis (Impact Factor: 3.16). 12/2008; 29(23):4618-26. DOI: 10.1002/elps.200800456
Source: PubMed

ABSTRACT The reference human genome provides an adequate basis for biological researchers to study the relationship between genotype and the associated phenotypes, but a large push is underway to sequence many more genomes to determine the role of various specificities among different individuals that control these relationships and to enable the use of human genome data for personalized and preventative healthcare. The current electrophoretic methodology for sequencing an entire mammalian genome, which includes standard molecular biology techniques for genomic sample preparation and the separation of DNA fragments using capillary array electrophoresis, remains far too expensive ($5 million) to make genome sequencing ubiquitous. The National Human Genome Research Institute has put forth goals to reduce the cost of human genome sequencing to $100,000 in the short term and $1000 in the long term to spur the innovative development of technologies that will permit the routine sequencing of human genomes for use as a diagnostic tool for disease. Since the announcement of these goals, several companies have developed and released new, non-electrophoresis-based sequencing instruments that enable massive throughput in the gathering of genomic information. In this review, we discuss the advantages and limitations of these new, massively parallel sequencers and compare them with the currently developing next generation of electrophoresis-based genetic analysis platforms, specifically microchip electrophoresis devices, in the context of three distinct types of genetic analysis.

  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypertrophic cardiomyopathy (HCM) is a primary disease of the cardiac muscle that occurs mainly due to mutations (>1,400 variants) in genes encoding for the cardiac sarcomere. HCM, the most common familial form of cardiomyopathy, affecting one in every 500 people in the general population, is typically inherited in an autosomal dominant pattern, and presents variable expressivity and age-related penetrance. Due to the morphological and pathological heterogeneity of the disease, the appearance and progression of symptoms is not straightforward. Most HCM patients are asymptomatic, but up to 25% develop significant symptoms, including chest pain and sudden cardiac death. Sudden cardiac death is a dramatic event, since it occurs without warning and mainly in younger people, including trained athletes. Molecular diagnosis of HCM is of the outmost importance, since it may allow detection of subjects carrying mutations on HCM-associated genes before development of clinical symptoms of HCM. However, due to the genetic heterogeneity of HCM, molecular diagnosis is difficult. Currently, there are mainly four techniques used for molecular diagnosis of HCM, including Sanger sequencing, high resolution melting, mutation detection using DNA arrays, and next-generation sequencing techniques. Application of these methods has proven successful for identification of mutations on HCM-related genes. This review summarizes the features of these technologies, highlighting their strengths and weaknesses. Furthermore, current therapeutics for HCM patients are correlated with clinically observed phenotypes and are based on the alleviation of symptoms. This is mainly due to insufficient knowledge on the mechanisms involved in the onset of HCM. Tissue engineering alongside regenerative medicine coupled with nanotherapeutics may allow fulfillment of those gaps, together with screening of novel therapeutic drugs and target delivery systems.
    The Application of Clinical Genetics 01/2014; 7:195-208. DOI:10.2147/TACG.S49126
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RNA expression studies have proved an essential step in the understanding of cell biology. Although in the last decade microarrays have been the assay of choice for ge-nomic studies, next generation sequencing applied to mRNA (RNA-Seq) has the potential to overcome them, becoming the new standard. The main difference between the two technolo-gies is that RNA-Seq yields counts rather than continuous measures of expression, leading to the need for new methods for the analysis of count data from a high-throughput technology. We present a hierarchical Bayesian Generalized Linear Model, to deal with RNA-Seq experiments. The model accounts for the difference in the total number of counts in the different samples (sequencing depth), as well as for overdispersion, with no need to transform the data prior to the analysis. Using an MCMC algorithm, we apply our model to real data. Comparing our results to those of edgeR (a state-of-the-art algorithm for RNA-Seq data), we show promising results both in terms of modelling and of testing for differential expression.


Available from